Novo Nordisk announced a substantial price reduction for its flagship weight-loss drug in China, with media reports indicating cuts of up to 48% on its highest monthly doses. The move, aimed at improving patient affordability and maintaining market share ahead of patent expiry next year, led investors to react swiftly: the company’s stock slipped by nearly 2% on the following trading day. With local competitors gearing up to launch biosimilar or alternative GLP-1 therapies and the semaglutide patent set to expire in 2026, the pricing adjustment highlights the balance Novo Nordisk is striking between competitive positioning and revenue preservation.

Despite groundbreaking approvals—most recently the first oral semaglutide formulation for chronic weight management—the share price has tumbled roughly 50% year to date, marking the worst performance since the company’s Stockholm listing. Investors cite fierce competition from rival drugmakers and compounding pharmacies offering cheaper formulations, as well as skepticism over the financial payoff from a late-stage Alzheimer’s trial that failed to meet its primary endpoint. Nonetheless, scientific stakeholders underscore Novo Nordisk’s deep pipeline and diversified GLP-1 franchise, including cardiovascular and renal indications, positioning the company for potential long-term gains once near-term market pressures ease.